PubMed Health⌕ Search

PubMed · 3067843

Primary aldosteronism.

Abstract

Patients with primary aldosteronism do not have distinctive clinical features. However, the associated hypertension is invariably high and often resistant to drug therapy. The recommended initial test in suspected primary aldosteronism is the determination of aldosterone excretion rate after salt loading. Patients in whom aldosterone excretion rates exceed 14.0 micrograms per 24 hours when the urinary sodium is at least 250 mEq per 24 hours are prime candidates for additional studies. The presence of hypokalemia and/or suppressed plasma renin activity provides corroborative evidence of primary aldosteronism, but the absence of either or both does not preclude the diagnosis. Spontaneous, moderately severe hypokalemia (less than 3.0 mEq per L), an anomalous postural decrease in plasma aldosterone concentration, and increased plasma 18-hydroxycorticosterone values (greater than 100 ng per dl) indicate the presence of an adenoma. For localization of an adenoma, an adrenal CT scan should be obtained first and is considered diagnostic if an adrenal mass is clearly identified. When the CT scan is inconclusive, adrenal venous sampling can be done for more definitive localization. In the presence of an adenoma, surgical excision is the recommended approach but only after pharmacologic normalization of arterial pressure and correction of metabolic abnormalities. Sustained salt and water depletion is the most important therapeutic goal for these patients, and cure can be achieved despite prolonged and severe hypertension.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E L Bravo. 1988. Primary aldosteronism.. https://pubmed.ncbi.nlm.nih.gov/3067843/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Global Genomic Surveillance.

Global genomic surveillance has emerged as a foundational pillar of public health in the twenty-first century, enabling real-time tracking of pathogen evolution and informing outbreak response. This chapter examines the strategic architecture of global genomic surveillance, focusing on its application to arboviruses such as chikungunya virus (CHIKV). It explores the integration of genomic data with epidemiological, clinical, and environmental information within a One Health framework, while addressing critical challenges in governance, equity, and interoperability. The discussion covers the entire genomic surveillance workflow, from sample collection and sequencing to bioinformatic analysis and phylogenetic inference, and highlights the transformative role of artificial intelligence (AI) in predictive surveillance. By analyzing global initiatives, operational barriers, and emerging technologies, this chapter underscores the necessity of sustainable, equitable, and interoperable genomic systems to proactively address current and future infectious disease threats.

Humans↗

Systematic Dissection of Key Driver Perturbation Signatures in Single Cells via ECCITE-seq.

CRISPR screens, such as expanded CRISPR-compatible cellular indexing of transcriptomes and epitopes by sequencing (ECCITE-seq), enable the simultaneous measurement of transcriptomes, gRNA identity, and cell-surface protein expression at single-cell resolution to systematically interrogate gene function. This platform provides a powerful and scalable experimental approach for validating disease-associated regulators identified by large-scale association studies and other computational methods, including network-based analyses of multi-omics data. Here, as an example application, we describe an ECCITE-seq framework to characterize the transcriptomic consequences of perturbing multiple neuronal key driver genes associated with Alzheimer's disease (AD) in human-induced pluripotent stem cell (hiPSC)-derived neurons. More broadly, by integrating customized pooled gRNA libraries with different CRISPR effectors across multiple cell types, this approach allows for the assessment of the regulatory impact of candidate genes implicated in development and disease processes.

Humans↗

Identification of Genome-Wide Chromatin Structural Aberration in Cancer by Hi-C Analysis.

Aberrant three-dimensional genome organization is a hallmark of cancer, often driving oncogene activation through mechanisms such as enhancer hijacking. High-throughput chromosome conformation capture (Hi-C) maps these interactions on a genome-wide scale. Unlike earlier dilution-based methods, in situ Hi-C performs proximity ligation within intact nuclei, minimizing random ligation noise and enabling fine-scale structure detection. This chapter describes an optimized in situ Hi-C protocol tailored for cancer cell lines using MboI digestion and biotin-mediated pull-down to generate high-complexity libraries. We further outline a computational workflow that extends beyond standard topological mapping of compartments and topologically associating domains to identify cancer-specific aberrations. Specifically, we focus on detecting chromosomal rearrangements (structural variants) and characterizing the distinct circular topology of extrachromosomal DNA. This integrated experimental and analytical framework provides the necessary tools to dissect the spatial dysregulation underlying tumor evolution.

Humans↗